WuXi Biologics Reports Solid 2023 Annual Results finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Revenue Increased by 17.8% Y-o-Y to RMB8,492.0 Million Adjusted Net Profit Rose by 0.4% to RMB2,925.6 Million Non-COVID Revenue Achieved 59.7% Y-o-Y Growth,.
The New EPICO3 Manufacturing Facility on-track for operation in 2024 meobserver.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from meobserver.org Daily Mail and Mail on Sunday newspapers.
WuXi Biologics Announced Global Strategic Partnership with Pharmadule Morimatsu at its Singapore CRDMO Center Project Singapore, June 26, 2023 - WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Res.